ArticleJCO precision oncology2025
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeWe performed spatial transcriptomics of estrogen receptor (ER)-negative, ER-low, and ER-high tumor regions of breast cancers that were intermediate (10%-60%) ER-positive by immunohistochemistry to better understand the intratumor heterogeneity in ER expression and to elucidate whether cells of different molecular subtypes (ie, Luminal A [LumA], Luminal B [LumB], human epidermal growth factor receptor 2-enriched, or Basal-like) can coexist in the same tumor.
methodsDigital spatial profiling was performed on 10 ER-heterogeneous (10%-60% ER+) and 10 ER-high (>60% ER+) primary breast cancers using the NanoString GeoMx platform with the Human Whole Transcriptome Atlas probe set.
resultsLumA and LumB molecular subtypes were intermixed, but there were no Basal-like populations in these ER-heterogeneous tumors. The ER-negative (ER-) regions were LumB-like and showed lower expression of
conclusionThis study demonstrates mixed Lum-A and Lum-B molecular subtypes within ER-intermediate primary breast cancers and reveals that ER- tumor cell populations have molecular features of endocrine resistance but chemotherapy sensitivity. These findings may explain the worse clinical outcomes of patients with ER-heterogeneous breast cancers and suggest benefit from combined endocrine and chemotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.